Therefore, at least two types of cancer cells share the requirement for Luzp4 for efficient growth and, given its restricted expression profile in non-disease states, it may be an appropriate target for development of drugs or immunotherapies to treat MM or melanoma. This evidence concerns the gene LUZP4 and Miyoshi myopathy.